KPV

• Inflammation support (unproven in humans)recommended

  Community practice, not from a label or trial: bottom of the 200-500 mcg subcutaneous range, once daily. Animal-only evidence.

• Community practice, not from a label or trial: 200 to 500 mcg per subcutaneous injection, once daily (oral capsules 1-2 times daily, no amount), cycles of 4 to 8 weeks or longer for chronic conditions (Peptide Protocol Wiki).
• Research models: 100 micromolar KPV in drinking water in mice, 10 nM in cells (PubMed 18061177). Not a human dose.

Route: Subcutaneous or oral (community). The mouse study used oral dosing.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Placeholder 5 mg vial plus 2.5 mL gives 2,000 mcg/mL, so 200 mcg is 10 units. This is arithmetic, not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

Cycles of 4 to 8 weeks, repeatable; rest length not stated.

Why:

• The source gives no rest period.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Not an FDA-approved drug. FDA removed it from the 503A Category 2 list on April 15 2026 because the nominators withdrew, which does not make it compoundable; a July 2026 advisory committee recommendation is not yet a rule. Check current status.

Common side effects:

• No human safety data were found.

Stop and call your prescriber if:

• Swelling, redness or pain spreading from the injection site
• Rash or trouble breathing
• Any new unexplained symptom

No reliable source names a biomarker for this compound.

• PubMed 18061177: PepT1-mediated KPV uptake reduces intestinal inflammation (Dalmasso 2008, cells and mice)
• Peptide Protocol Wiki KPV page: dose, frequency, cycle, no human trials (secondary source)
• Frier Levitt: FDA removes 12 peptides from Category 2 (April 2026)
• McDermott: advisory committee recommends KPV for the 503A list (8-6, July 2026)